Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (51-60 of 434) with videos related to

Pageof 44
Sort By:
Expert Opinion on Drug Safety|November 4, 2014
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancerThor Chalmer, Thomas P Almdal, Tina Vilsbøll, et al.
Therapeutic Advances in Endocrinology and Metabolism|June 4, 2020
Hypoglycaemia and cardiac arrhythmias in diabetesAndreas Andersen, Peter G Jørgensen, Filip K Knop, et al.
The Review of Diabetic Studies : RDS|January 21, 2012
Therapy for obesity based on gastrointestinal hormonesJonatan I Bagger, Mikkel Christensen, Filip K Knop, et al.
The Review of Diabetic Studies : RDS|January 21, 2012
The alpha-cell as target for type 2 diabetes therapyMikkel Christensen, Jonatan I Bagger, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|February 23, 2021
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weightSimone Theilade, Mikkel B Christensen, Tina Vilsbøll, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 14, 2015
Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacyAndreas Brønden, Signe V Naver, Filip K Knop, et al.
Acta Ophthalmologica|July 7, 2015
Retinal vascular and structural dynamics during acute hyperglycaemiaOliver N Klefter, Tina Vilsbøll, Filip K Knop, et al.
Diseases of the Colon and Rectum|December 29, 2004
Delayed ischemic cecal perforation despite optimal decompression after placement of a self-expanding metal stent: report of a caseFilip K Knop, Bo Pilsgaard, Søren Meisner, et al.
Idrugs : the Investigational Drugs Journal|July 25, 2009
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Jens J Holst, et al.
Expert Opinion on Drug Safety|January 20, 2017
Cardiovascular safety and benefits of GLP-1 receptor agonistsNiels B Dalsgaard, Andreas Brønden, Tina Vilsbøll, et al.
Pageof 44

Showing results (51-60 of 434) with videos related to

Sort By:
Pageof 44
Expert Opinion on Drug Safety|November 4, 2014
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancerThor Chalmer, Thomas P Almdal, Tina Vilsbøll, et al.
Therapeutic Advances in Endocrinology and Metabolism|June 4, 2020
Hypoglycaemia and cardiac arrhythmias in diabetesAndreas Andersen, Peter G Jørgensen, Filip K Knop, et al.
The Review of Diabetic Studies : RDS|January 21, 2012
Therapy for obesity based on gastrointestinal hormonesJonatan I Bagger, Mikkel Christensen, Filip K Knop, et al.
The Review of Diabetic Studies : RDS|January 21, 2012
The alpha-cell as target for type 2 diabetes therapyMikkel Christensen, Jonatan I Bagger, Tina Vilsbøll, et al.
Diabetes, Obesity & Metabolism|February 23, 2021
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weightSimone Theilade, Mikkel B Christensen, Tina Vilsbøll, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 14, 2015
Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacyAndreas Brønden, Signe V Naver, Filip K Knop, et al.
Acta Ophthalmologica|July 7, 2015
Retinal vascular and structural dynamics during acute hyperglycaemiaOliver N Klefter, Tina Vilsbøll, Filip K Knop, et al.
Diseases of the Colon and Rectum|December 29, 2004
Delayed ischemic cecal perforation despite optimal decompression after placement of a self-expanding metal stent: report of a caseFilip K Knop, Bo Pilsgaard, Søren Meisner, et al.
Idrugs : the Investigational Drugs Journal|July 25, 2009
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Jens J Holst, et al.
Expert Opinion on Drug Safety|January 20, 2017
Cardiovascular safety and benefits of GLP-1 receptor agonistsNiels B Dalsgaard, Andreas Brønden, Tina Vilsbøll, et al.
Pageof 44